查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1858787

Iloprost类药物：全球市场份额和排名、总销售额和需求预测（2025-2031 年）

Iloprost Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 74 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球Iloprost药物市场规模预计为 6,234 万美元，预计到 2031 年将萎缩至 4,498 万美元，2025 年至 2031 年的复合年增长率为 -4.6%。

Iloprost是一种用于治疗血管收缩、组织血流受限疾病的药物，例如肺动脉高压（PAH）、硬皮症和雷诺氏现象。 2024年，Iloprost的全球产量约为104万单位，全球平均市场价格约为每单位60美元。

近年来，肺动脉高压（PAH）及相关血管疾病已成为许多国家和地区的公共卫生重点，各国政府和监管机构更新了临床指南，以提高诊断率和早期疗育。这为Iloprost的广泛应用奠定了製度基础。尤其值得一提的是，美国FDA核准Iloprost素注射液（Auramin）用于治疗严重冻伤，并认可其可降低截肢风险，这标誌着伊洛前列素的应用范围超越了传统的PAH适应症，极大地增强了製药公司和投资者对这一新兴治疗领域潜力的信心。此外，医疗服务提供者日益重视改善微循环和降低血管阻力以改善患者预后，加之患者和临床医生对慢性维持治疗和急性介入治疗的需求不断增长，这些因素共同推动了给药方式（吸入、静脉注射）和器械便捷性的创新。学名药的上市以及某些地区的生命週期管理也有助于降低成本并扩大用药范围。

儘管Iloprost具有很高的成长潜力，但它也面临一些限制。治疗费用相对较高，尤其是在需要使用专用吸入或雾化装置、输注系统或住院给药的情况下。各国的保险覆盖范围和报销政策差异很大，这可能会限制其广泛应用和普及。副作用和耐受性问题（例如低血压、脸部潮红、咳嗽和气道刺激以及头痛）需要密切的临床监测和剂量调整，这可能会降低用药的便利性和患者的依从性。新适应症的核准流程可能很漫长，并且需要强有力的临床证据来证明其在新用途的安全性和有效性。同时，专利到期和学名药的竞争威胁着现有品牌产品的利润率。此外，基础设施负担——包括设备、给药系统、分销和物流以及必要的低温运输——也构成挑战，尤其是在新兴市场和资源匮乏的市场。

从临床和患者的观点来看，对Iloprost的需求正朝着更多样化、个体化和便利的方向发展。医生和患者越来越期望Iloprost能够用于慢性疾病管理（例如肺动脉高压）和急性治疗（例如冻伤和血管损伤），并能快速起效，显着改善患者的生活品质。改良的吸入製剂——更小巧、更便携的雾化器、更少的每日剂量以及更易于使用的吸入系统——正成为强劲的需求驱动因素。平衡患者依从性和长期疗效变得日益重要。临床医生越来越关注伊洛前列素与其他肺动脉高压药物联合治疗以及作为缺血性和循环衰竭的辅助/辅助性治疗的潜在用途。在新兴市场，不断扩大的公共保险和医疗保健体系显着增加了对经济有效的Iloprost产品和学名药药的需求。同时，人们也越来越期待该药物能核准用于治疗冻伤、血管性皮肤病和微循环障碍等新适应症，并进行相应的临床试验。

上游原料和生产流程对Iloprost的品质、成本和供应稳定性有着深远的影响。Iloprost的合成需要高纯度的有机化学中间体，这些中间体含有双环结构、不饱和碳链、羟基和烯烃官能基以及特定的前列腺环素样结构。必须严格控制立体化学和杂质谱（包括异构体、残留金属催化剂和溶剂残留）。此外，吸入或静脉注射製剂需要高纯度且符合药典/GMP标准的添加剂、溶剂、缓衝系统和稳定剂。关键催化剂、金属错合、精细化学中间体和溶剂的供应可能受到原材料短缺、环境法规（特别是对有机溶剂排放和废弃物处理的要求）、进出口限制以及供应商资质要求的限制。吸入装置中使用的材料（例如塑胶零件、雾化器头、过滤器）及其环境稳定性也会影响生产投资和整体成本结构。该产品的毛利率约为80%。

本报告旨在按地区/国家、类型和应用对全球Iloprost药物市场进行全面分析，重点关注总销售额、市场份额和主要企业的排名。

Iloprost药物市场规模、估算和预测均以销售收入为指标，以2024年为基准年，并包含2020年至2031年的历史数据和预测数据。我们运用定量和定性分析，帮助读者制定业务/成长策略，评估市场竞争格局，分析公司在当前市场中的地位，并就Iloprost药物做出明智的商业决策。

市场区隔

公司

  • Actelion（J & J）
  • Bayer AG
  • Teva
  • Eastpharma
  • Zentiva

按类型分類的细分市场

  • 吸入
  • 静脉

应用领域

  • 医院
  • 诊所

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Iloprost Drugs was estimated to be worth US$ 62.34 million in 2024 and is forecast to a readjusted size of US$ 44.98 million by 2031 with a CAGR of -4.6% during the forecast period 2025-2031.

Iloprost is a drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and other diseases in which the blood vessels are constricted and blood can't flow to the tissues.In 2024, global Iloprost drug production reached approximately 1.04 m units, with an average global market price of around US$ 60 per unit.

In recent years, pulmonary arterial hypertension (PAH) and related vascular diseases have been designated as public health priorities in many countries and regions, with governmental and regulatory bodies updating clinical guidelines to improve diagnosis rates and early intervention. This creates institutional channels for broader adoption of Iloprost. Notably, the US FDA's approval of Iloprost injection (Aurlumyn) for severe frostbite to reduce the risk of amputation marks a landmark extension beyond traditional PAH indications, boosting confidence among pharmaceutical companies and investors in its potential in new therapeutic areas. In addition, healthcare providers' increased emphasis on improving microcirculation and reducing vascular resistance to enhance patient outcomes, together with rising demand from patients and clinicians for both chronic maintenance and acute intervention therapies, propel innovation in delivery modes (inhalation, intravenous) and device convenience. Generic entry and lifecycle management in some jurisdictions also contribute to cost reduction and increased access.

Even with strong growth potential, Iloprost faces several constraints. The cost of treatment is relatively high, especially when specialized inhalation or nebulization devices, infusion systems, or hospital-based administration are required; insurance or reimbursement coverage varies widely between countries, which may hinder uptake and accessibility. The side effect profile and tolerability issues (hypotension, flushing, cough or airway irritation, headache, etc.) require careful clinical monitoring and dosing adjustments, which may reduce convenience and patient compliance. Regulatory pathways for new indications can be lengthy, and demonstrating safety and efficacy in novel applications demands robust clinical evidence; meanwhile, patent expirations and generic competition pose threats to established branded products' margins. Also, the infrastructure burden-devices, delivery systems, distribution/logistics, cold chain where applicable-pose challenges, especially in emerging or low-resource markets.

Clinically and from the patient perspective, demand for Iloprost is moving toward greater diversity, personalization, and convenience. Physicians and patients increasingly expect Iloprost to address both chronic management (such as in PAH) and acute interventions (such as frostbite or vascular injury), with rapid onset of action and measurable improvements in life quality. Improvements in inhaled formulations-smaller, more portable nebulizers, fewer daily doses, better user-friendly inhaler systems-are emerging as strong demand points. Patient adherence vs long-term efficacy balance is of growing importance. Clinician interest in combination therapies with other PAH agents, or exploring supportive/adjuvant use in ischemic or circulatory-deficit conditions, is increasing. In emerging markets, as public insurance / health systems expand, demand for cost-effective versions or generic Iloprost increases significantly. Concurrently, there is rising anticipation for regulatory recognition of new indications and supportive clinical trials in frostbite, vascular skin disorders, and microcirculation-related conditions.

The upstream raw materials and manufacturing processes deeply affect Iloprost's quality, cost, and supply stability. Synthesis of Iloprost involves high-purity organic chemical intermediates encompassing bicyclic ring systems, unsaturated carbon chains, hydroxyl and alkene functional groups, and the specific prostacyclin-analogous framework, requiring strict control of stereochemistry and impurity profile (including isomers, residual metal catalysts, solvent residues, etc.). Moreover, formulations for inhaled or intravenous use demand excipients, solvents, buffer systems, stabilizers that meet high purity and pharmacopeial / GMP standards. Key catalysts, metal complexes, fine chemical intermediates and solvents may be limited by raw material scarcity, environmental regulation (especially organic solvent emissions and waste disposal), import/export controls, and supplier qualification and certification requirements. The materials used in inhalation devices (plastic components, nebulizer heads, filters, etc.) and their environmental stability also affect production investment and overall cost structure.The gross profit margin of this product is around 80%.

This report aims to provide a comprehensive presentation of the global market for Iloprost Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Iloprost Drugs by region & country, by Type, and by Application.

The Iloprost Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Iloprost Drugs.

Market Segmentation

By Company

  • Actelion (J & J)
  • Bayer AG
  • Teva
  • Eastpharma
  • Zentiva

Segment by Type

  • Inhaled
  • Intravenous

Segment by Application

  • Hospital
  • Clinic

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Iloprost Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Iloprost Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Iloprost Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Iloprost Drugs Product Introduction
  • 1.2 Global Iloprost Drugs Market Size Forecast (2020-2031)
  • 1.3 Iloprost Drugs Market Trends & Drivers
    • 1.3.1 Iloprost Drugs Industry Trends
    • 1.3.2 Iloprost Drugs Market Drivers & Opportunity
    • 1.3.3 Iloprost Drugs Market Challenges
    • 1.3.4 Iloprost Drugs Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Iloprost Drugs Players Revenue Ranking (2024)
  • 2.2 Global Iloprost Drugs Revenue by Company (2020-2025)
  • 2.3 Key Companies Iloprost Drugs Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Iloprost Drugs Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Iloprost Drugs
  • 2.6 Iloprost Drugs Market Competitive Analysis
    • 2.6.1 Iloprost Drugs Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Iloprost Drugs Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Iloprost Drugs as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Inhaled
    • 3.1.2 Intravenous
  • 3.2 Global Iloprost Drugs Sales Value by Type
    • 3.2.1 Global Iloprost Drugs Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Iloprost Drugs Sales Value, by Type (2020-2031)
    • 3.2.3 Global Iloprost Drugs Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Hospital
    • 4.1.2 Clinic
  • 4.2 Global Iloprost Drugs Sales Value by Application
    • 4.2.1 Global Iloprost Drugs Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Iloprost Drugs Sales Value, by Application (2020-2031)
    • 4.2.3 Global Iloprost Drugs Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Iloprost Drugs Sales Value by Region
    • 5.1.1 Global Iloprost Drugs Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Iloprost Drugs Sales Value by Region (2020-2025)
    • 5.1.3 Global Iloprost Drugs Sales Value by Region (2026-2031)
    • 5.1.4 Global Iloprost Drugs Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Iloprost Drugs Sales Value, 2020-2031
    • 5.2.2 North America Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Iloprost Drugs Sales Value, 2020-2031
    • 5.3.2 Europe Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Iloprost Drugs Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Iloprost Drugs Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Iloprost Drugs Sales Value, 2020-2031
    • 5.5.2 South America Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Iloprost Drugs Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Iloprost Drugs Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Iloprost Drugs Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Iloprost Drugs Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Iloprost Drugs Sales Value, 2020-2031
    • 6.3.2 United States Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Iloprost Drugs Sales Value, 2020-2031
    • 6.4.2 Europe Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Iloprost Drugs Sales Value, 2020-2031
    • 6.5.2 China Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Iloprost Drugs Sales Value, 2020-2031
    • 6.6.2 Japan Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Iloprost Drugs Sales Value, 2020-2031
    • 6.7.2 South Korea Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Iloprost Drugs Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Iloprost Drugs Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Iloprost Drugs Sales Value, 2020-2031
    • 6.9.2 India Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Iloprost Drugs Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Actelion (J & J)
    • 7.1.1 Actelion (J & J) Profile
    • 7.1.2 Actelion (J & J) Main Business
    • 7.1.3 Actelion (J & J) Iloprost Drugs Products, Services and Solutions
    • 7.1.4 Actelion (J & J) Iloprost Drugs Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Actelion (J & J) Recent Developments
  • 7.2 Bayer AG
    • 7.2.1 Bayer AG Profile
    • 7.2.2 Bayer AG Main Business
    • 7.2.3 Bayer AG Iloprost Drugs Products, Services and Solutions
    • 7.2.4 Bayer AG Iloprost Drugs Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Bayer AG Recent Developments
  • 7.3 Teva
    • 7.3.1 Teva Profile
    • 7.3.2 Teva Main Business
    • 7.3.3 Teva Iloprost Drugs Products, Services and Solutions
    • 7.3.4 Teva Iloprost Drugs Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Teva Recent Developments
  • 7.4 Eastpharma
    • 7.4.1 Eastpharma Profile
    • 7.4.2 Eastpharma Main Business
    • 7.4.3 Eastpharma Iloprost Drugs Products, Services and Solutions
    • 7.4.4 Eastpharma Iloprost Drugs Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Eastpharma Recent Developments
  • 7.5 Zentiva
    • 7.5.1 Zentiva Profile
    • 7.5.2 Zentiva Main Business
    • 7.5.3 Zentiva Iloprost Drugs Products, Services and Solutions
    • 7.5.4 Zentiva Iloprost Drugs Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Zentiva Recent Developments

8 Industry Chain Analysis

  • 8.1 Iloprost Drugs Industrial Chain
  • 8.2 Iloprost Drugs Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Iloprost Drugs Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Iloprost Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Iloprost Drugs Market Trends
  • Table 2. Iloprost Drugs Market Drivers & Opportunity
  • Table 3. Iloprost Drugs Market Challenges
  • Table 4. Iloprost Drugs Market Restraints
  • Table 5. Global Iloprost Drugs Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Iloprost Drugs Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Iloprost Drugs Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Iloprost Drugs Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Iloprost Drugs
  • Table 10. Global Iloprost Drugs Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Iloprost Drugs as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Iloprost Drugs Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Iloprost Drugs Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Iloprost Drugs Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Iloprost Drugs Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Iloprost Drugs Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Iloprost Drugs Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Iloprost Drugs Sales Value by Application (2020-2025) & (US$ Million)
  • Table 20. Global Iloprost Drugs Sales Value by Application (2026-2031) & (US$ Million)
  • Table 21. Global Iloprost Drugs Sales Market Share in Value by Application (2020-2025)
  • Table 22. Global Iloprost Drugs Sales Market Share in Value by Application (2026-2031)
  • Table 23. Global Iloprost Drugs Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Iloprost Drugs Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Iloprost Drugs Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Iloprost Drugs Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Iloprost Drugs Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Iloprost Drugs Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Iloprost Drugs Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Iloprost Drugs Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Actelion (J & J) Basic Information List
  • Table 32. Actelion (J & J) Description and Business Overview
  • Table 33. Actelion (J & J) Iloprost Drugs Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Iloprost Drugs Business of Actelion (J & J) (2020-2025)
  • Table 35. Actelion (J & J) Recent Developments
  • Table 36. Bayer AG Basic Information List
  • Table 37. Bayer AG Description and Business Overview
  • Table 38. Bayer AG Iloprost Drugs Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Iloprost Drugs Business of Bayer AG (2020-2025)
  • Table 40. Bayer AG Recent Developments
  • Table 41. Teva Basic Information List
  • Table 42. Teva Description and Business Overview
  • Table 43. Teva Iloprost Drugs Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Iloprost Drugs Business of Teva (2020-2025)
  • Table 45. Teva Recent Developments
  • Table 46. Eastpharma Basic Information List
  • Table 47. Eastpharma Description and Business Overview
  • Table 48. Eastpharma Iloprost Drugs Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Iloprost Drugs Business of Eastpharma (2020-2025)
  • Table 50. Eastpharma Recent Developments
  • Table 51. Zentiva Basic Information List
  • Table 52. Zentiva Description and Business Overview
  • Table 53. Zentiva Iloprost Drugs Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Iloprost Drugs Business of Zentiva (2020-2025)
  • Table 55. Zentiva Recent Developments
  • Table 56. Key Raw Materials Lists
  • Table 57. Raw Materials Key Suppliers Lists
  • Table 58. Iloprost Drugs Downstream Customers
  • Table 59. Iloprost Drugs Distributors List
  • Table 60. Research Programs/Design for This Report
  • Table 61. Key Data Information from Secondary Sources
  • Table 62. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Iloprost Drugs Product Picture
  • Figure 2. Global Iloprost Drugs Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Iloprost Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Iloprost Drugs Report Years Considered
  • Figure 5. Global Iloprost Drugs Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Iloprost Drugs Revenue in 2024
  • Figure 7. Iloprost Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Inhaled Picture
  • Figure 9. Intravenous Picture
  • Figure 10. Global Iloprost Drugs Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Iloprost Drugs Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Hospital
  • Figure 13. Product Picture of Clinic
  • Figure 14. Global Iloprost Drugs Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Iloprost Drugs Sales Value Market Share by Application, 2024 & 2031
  • Figure 16. North America Iloprost Drugs Sales Value (2020-2031) & (US$ Million)
  • Figure 17. North America Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 18. Europe Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 19. Europe Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Asia Pacific Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Asia Pacific Iloprost Drugs Sales Value by Region (%), 2024 VS 2031
  • Figure 22. South America Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. South America Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Middle East & Africa Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Middle East & Africa Iloprost Drugs Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Key Countries/Regions Iloprost Drugs Sales Value (%), (2020-2031)
  • Figure 27. United States Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. United States Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 29. United States Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 30. Europe Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Europe Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 32. Europe Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 33. China Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. China Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 35. China Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 36. Japan Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Japan Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Japan Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 39. South Korea Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. South Korea Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 41. South Korea Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 42. Southeast Asia Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Southeast Asia Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Southeast Asia Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 45. India Iloprost Drugs Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. India Iloprost Drugs Sales Value by Type (%), 2024 VS 2031
  • Figure 47. India Iloprost Drugs Sales Value by Application (%), 2024 VS 2031
  • Figure 48. Iloprost Drugs Industrial Chain
  • Figure 49. Iloprost Drugs Manufacturing Cost Structure
  • Figure 50. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 51. Bottom-up and Top-down Approaches for This Report
  • Figure 52. Data Triangulation
  • Figure 53. Key Executives Interviewed